# Cholinesterase and Neurodegenerative Diseases

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/cholinesterase-and-neurodegenerative-diseases/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the pharmacology and toxicology of cholinesterase inhibitors, particularly acetylcholinesterase and butyrylcholinesterase, in the context of neurodegenerative diseases such as Alzheimer's. It explores the development of multi-target-directed ligands, novel drug therapies, and the implications for cognitive deficits. The research also delves into the structure, function, and regulation of cholinesterases, as well as their potential roles in neuroprotection and neurorestoration. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t12023 |
| Works | 166 |

## Topic papers all

Showing 15 of 166.

- [Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease](https://scholariq.org/papers/toward-defining-the-preclinical-stages-of-alzheimer-s-disease-recommendations/)
- [Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis](https://scholariq.org/papers/mutations-in-cu-zn-superoxide-dismutase-gene-are-associated-with-familial/)
- [The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease](https://scholariq.org/papers/the-cholinergic-system-in-the-pathophysiology-and-treatment-of-alzheimer-s/)
- [Revising the definition of Alzheimer's disease: a new lexicon](https://scholariq.org/papers/revising-the-definition-of-alzheimer-s-disease-a-new-lexicon/)
- [Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors](https://scholariq.org/papers/crystal-structure-of-an-ach-binding-protein-reveals-the-ligand-binding-domain-of/)
- [Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior](https://scholariq.org/papers/acetylcholine-as-a-neuromodulator-cholinergic-signaling-shapes-nervous-system/)
- [Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro](https://scholariq.org/papers/curcumin-has-potent-anti-amyloidogenic-effects-for-alzheimer-s-amyloid-fibrils/)
- [Alzheimer's disease: clinical trials and drug development](https://scholariq.org/papers/alzheimer-s-disease-clinical-trials-and-drug-development/)
- [Neuropsychiatric symptoms in Alzheimer's disease](https://scholariq.org/papers/neuropsychiatric-symptoms-in-alzheimer-s-disease/)
- [Current and Future Treatments in Alzheimer Disease: An Update](https://scholariq.org/papers/current-and-future-treatments-in-alzheimer-disease-an-update/)
- [Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria](https://scholariq.org/papers/amyotrophic-lateral-sclerosis-frontotemporal-spectrum-disorder-als-ftsd-revised/)
- [Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline](https://scholariq.org/papers/effectiveness-of-cholinesterase-inhibitors-and-memantine-for-treating-dementia/)
- [Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease](https://scholariq.org/papers/donepezil-and-memantine-for-moderate-to-severe-alzheimer-s-disease/)
- [Modeling Alzheimer’s Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular Aβ and Differential Drug Responsiveness](https://scholariq.org/papers/modeling-alzheimer-s-disease-with-ipscs-reveals-stress-phenotypes-associated/)
- [A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD](https://scholariq.org/papers/a-1-year-randomized-placebo-controlled-study-of-donepezil-in-patients-with-mild/)

## Topic primary papers

Showing 15 of 41.

- [The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease](https://scholariq.org/papers/the-cholinergic-system-in-the-pathophysiology-and-treatment-of-alzheimer-s/)
- [Current and Future Treatments in Alzheimer Disease: An Update](https://scholariq.org/papers/current-and-future-treatments-in-alzheimer-disease-an-update/)
- [The cholinergic system and Parkinson disease](https://scholariq.org/papers/the-cholinergic-system-and-parkinson-disease/)
- [Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:](https://scholariq.org/papers/cholinesterase-inhibitors-for-the-treatment-of-alzheimer-s-disease/)
- [The developmental multiplicity and isoenzyme status of cavian esterases](https://scholariq.org/papers/the-developmental-multiplicity-and-isoenzyme-status-of-cavian-esterases/)
- [A phase II trial of huperzine A in mild to moderate Alzheimer disease](https://scholariq.org/papers/a-phase-ii-trial-of-huperzine-a-in-mild-to-moderate-alzheimer-disease/)
- [Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease](https://scholariq.org/papers/heterogeneity-and-selectivity-of-the-degeneration-of-cholinergic-neurons-in-the/)
- [Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins](https://scholariq.org/papers/recommended-nomenclature-for-five-mammalian-carboxylesterase-gene-families-human/)
- [Decreased Catalase Activity but Unchanged Superoxide Dismutase Activity in Brains of Patients with Dementia of Alzheimer Type](https://scholariq.org/papers/decreased-catalase-activity-but-unchanged-superoxide-dismutase-activity-in/)
- [Drosophila NMNAT Maintains Neural Integrity Independent of Its NAD Synthesis Activity](https://scholariq.org/papers/drosophila-nmnat-maintains-neural-integrity-independent-of-its-nad-synthesis/)
- [Comparison of therapeutic efficacy of neuroses between CM6912 (ethyl loflazepate) and diazepam in a double-blind trial](https://scholariq.org/papers/comparison-of-therapeutic-efficacy-of-neuroses-between-cm6912-ethyl-loflazepate/)
- [Rivastigmine in the treatment of Alzheimer's disease: an update](https://scholariq.org/papers/rivastigmine-in-the-treatment-of-alzheimer-s-disease-an-update/)
- [Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer’s Disease: Design, Synthesis, and Characterization of Pyrazines](https://scholariq.org/papers/discovery-of-novel-potent-and-highly-selective-glycogen-synthase-kinase-3-gsk3/)
- [Novel Tacrine–Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography](https://scholariq.org/papers/novel-tacrine-benzofuran-hybrids-as-potent-multitarget-directed-ligands-for-the/)
- [Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress](https://scholariq.org/papers/alzheimer-s-disease-updated-multi-targets-therapeutics-are-in-clinical-and-in/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.